CL2021000152A1 - Sulfonylurea compounds as inhibitors of interleukin 1 activity - Google Patents
Sulfonylurea compounds as inhibitors of interleukin 1 activityInfo
- Publication number
- CL2021000152A1 CL2021000152A1 CL2021000152A CL2021000152A CL2021000152A1 CL 2021000152 A1 CL2021000152 A1 CL 2021000152A1 CL 2021000152 A CL2021000152 A CL 2021000152A CL 2021000152 A CL2021000152 A CL 2021000152A CL 2021000152 A1 CL2021000152 A1 CL 2021000152A1
- Authority
- CL
- Chile
- Prior art keywords
- interleukin
- inhibitors
- activity
- sulfonylurea compounds
- nlrp3
- Prior art date
Links
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación se refiere a compuestos de sulfonilurea y compuestos relacionados útiles en el tratamiento de un trastorno sensible a la modulación de citocinas tales como IL-1ß e IL-18, modulación de NLRP3 o inhibición de la activación de NLRP3 o componentes relacionados del proceso inflamatorio.The present disclosure relates to sulfonylurea compounds and related compounds useful in the treatment of a disorder sensitive to the modulation of cytokines such as IL-1ß and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the process. inflammatory.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000152A1 true CL2021000152A1 (en) | 2021-07-09 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000152A CL2021000152A1 (en) | 2018-07-20 | 2021-01-19 | Sulfonylurea compounds as inhibitors of interleukin 1 activity |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (en) |
| EP (1) | EP3823726A1 (en) |
| JP (1) | JP7411631B2 (en) |
| KR (1) | KR20210034588A (en) |
| CN (1) | CN112437683A (en) |
| AR (1) | AR117617A1 (en) |
| AU (1) | AU2019305095A1 (en) |
| BR (1) | BR112021001012A2 (en) |
| CA (1) | CA3104199A1 (en) |
| CL (1) | CL2021000152A1 (en) |
| CO (1) | CO2021000817A2 (en) |
| CR (1) | CR20210024A (en) |
| IL (1) | IL280139A (en) |
| MA (1) | MA53170A (en) |
| MX (1) | MX2021000660A (en) |
| PE (1) | PE20211049A1 (en) |
| PH (1) | PH12020552155A1 (en) |
| SG (1) | SG11202012159TA (en) |
| TW (1) | TW202019937A (en) |
| WO (1) | WO2020018970A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA47308A (en) | 2017-01-23 | 2019-11-27 | Genentech Inc | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY |
| BR112020003014A2 (en) | 2017-08-15 | 2020-07-28 | Inflazome Limited | sulfonylureas and sulfonylthioureas as inhibitors of vnlrp3 |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| RU2020115098A (en) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | COMPOUNDS OF NEW SULFONAMIDE CARBOXAMIDES |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| UA128558C2 (en) | 2018-07-20 | 2024-08-14 | Ф. Хоффманн-Ля Рош Аг | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN114008030A (en) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | Fused 1,2-thiazoles and 1,2-thiazines as modulators of NLRP3 |
| US11976054B2 (en) | 2019-11-12 | 2024-05-07 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Amide derivative and preparation method therefore and use thereof in medicine |
| KR20230028425A (en) | 2020-06-19 | 2023-02-28 | 에이씨 이뮨 에스에이 | Dihydrooxazole and thiourea or urea derivatives that modulate the NLRP3 inflammasome pathway |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| CN119110803A (en) | 2022-02-21 | 2024-12-10 | 唯久生物技术(苏州)有限公司 | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
| EP4554945A1 (en) | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| CN119998284A (en) | 2022-07-28 | 2025-05-13 | Ac免疫有限公司 | New compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| AU723895B2 (en) * | 1997-01-29 | 2000-09-07 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| BR0014003A (en) | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Combination treatment with compounds of diaryl sufonil urea and il-1ra |
| MXPA04002565A (en) | 2001-11-30 | 2004-05-31 | Pfizer Prod Inc | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation. |
| CA3009937C (en) * | 2010-02-22 | 2020-12-15 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| US20140221340A1 (en) | 2011-09-02 | 2014-08-07 | Kyowa Hakko Kirin Co., Ltd. | Chemokine receptor activity regulator |
| IL273065B2 (en) | 2015-02-16 | 2024-01-01 | Univ Queensland | Sulfonylureas and related compounds and use of same |
| CN109071454B (en) * | 2016-02-16 | 2023-02-17 | 昆士兰大学 | Sulfonylureas and related compounds and uses thereof |
| AU2017253937B2 (en) | 2016-04-18 | 2021-08-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2855732T3 (en) | 2016-04-18 | 2021-09-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| MA47308A (en) * | 2017-01-23 | 2019-11-27 | Genentech Inc | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY |
| AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MA56075A (en) | 2017-07-07 | 2022-04-06 | Inflazome Ltd | NEW CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019034696A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019034688A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| BR112020003014A2 (en) | 2017-08-15 | 2020-07-28 | Inflazome Limited | sulfonylureas and sulfonylthioureas as inhibitors of vnlrp3 |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| AU2018317794A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | Novel substituted sulfonylurea derivatives |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| RU2020115098A (en) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | COMPOUNDS OF NEW SULFONAMIDE CARBOXAMIDES |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| JP2021529187A (en) | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | NLRP modulator |
| KR20210030947A (en) | 2018-07-03 | 2021-03-18 | 노파르티스 아게 | Methods of treatment or selection of therapeutic agents for TNF inhibitor-resistant subjects using NLRP3 antagonists |
| TWI811400B (en) | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | Further substituted triazolo quinoxaline derivatives |
| UA128558C2 (en) | 2018-07-20 | 2024-08-14 | Ф. Хоффманн-Ля Рош Аг | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| SG11202101480XA (en) | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| CN113056451A (en) | 2018-10-24 | 2021-06-29 | 诺华股份有限公司 | Compounds and compositions for treating conditions associated with NLRP activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| JP2022533287A (en) | 2019-01-22 | 2022-07-22 | ノバルティス アーゲー | Compounds and compositions for treating conditions associated with NLRP activity |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
-
2019
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/en active Active
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/en not_active Withdrawn
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/en not_active Application Discontinuation
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/en active Pending
- 2019-07-19 CA CA3104199A patent/CA3104199A1/en active Pending
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/en not_active Application Discontinuation
- 2019-07-19 MA MA053170A patent/MA53170A/en unknown
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/en unknown
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/en active Pending
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/en unknown
- 2019-07-19 CR CR20210024A patent/CR20210024A/en unknown
- 2019-07-22 AR ARP190102054A patent/AR117617A1/en not_active Application Discontinuation
- 2019-07-22 TW TW108125890A patent/TW202019937A/en unknown
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/en unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11560391B2 (en) | 2023-01-24 |
| PH12020552155A1 (en) | 2021-07-05 |
| WO2020018970A1 (en) | 2020-01-23 |
| PE20211049A1 (en) | 2021-06-04 |
| CN112437683A (en) | 2021-03-02 |
| IL280139A (en) | 2021-03-01 |
| AU2019305095A1 (en) | 2020-12-17 |
| KR20210034588A (en) | 2021-03-30 |
| JP7411631B2 (en) | 2024-01-11 |
| EP3823726A1 (en) | 2021-05-26 |
| CA3104199A1 (en) | 2020-01-23 |
| CO2021000817A2 (en) | 2021-02-17 |
| AR117617A1 (en) | 2021-08-18 |
| CR20210024A (en) | 2021-02-22 |
| SG11202012159TA (en) | 2021-01-28 |
| JP2021530536A (en) | 2021-11-11 |
| MX2021000660A (en) | 2021-03-25 |
| TW202019937A (en) | 2020-06-01 |
| MA53170A (en) | 2021-05-26 |
| US20210261568A1 (en) | 2021-08-26 |
| BR112021001012A2 (en) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000152A1 (en) | Sulfonylurea compounds as inhibitors of interleukin 1 activity | |
| CO2021001530A2 (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| CO2019009036A2 (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| MX2018005925A (en) | Purinones as ubiquitin-specific protease 1 inhibitors. | |
| CL2019001709A1 (en) | Pyrazole derivatives as malt1 inhibitors. | |
| PH12022550098A1 (en) | Parp1 inhibitors | |
| CO2017006997A2 (en) | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | |
| JOP20190194A1 (en) | Dicyclic nucleotides for the treatment of cancer | |
| MX2022007754A (en) | Novel il2 agonists and methods of use thereof. | |
| ECSP20018487A (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS | |
| MX2025003445A (en) | Heterobicyclic amides as inhibitors of cd38 | |
| MX384213B (en) | PEPTIDE INHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES. | |
| MX2017004234A (en) | Egfr inhibitor, and preparation and application thereof. | |
| CL2015002194A1 (en) | Erk inhibitors and their uses | |
| MX2020004724A (en) | C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY. | |
| EA202091731A1 (en) | AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS | |
| CU20200041A7 (en) | SUBSTITUTE IMIDAZOPYRIDINE AMIDES | |
| MX2019010554A (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors. | |
| UY34615A (en) | NEW USEFUL COMPOUNDS FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | |
| MX2021001471A (en) | SUBSTITUTED BENZIMIDAZOLES AS INHIBITORS OF PEPTIDYL ARGININE DEIMINASE 4 (PAD4). | |
| CL2022003348A1 (en) | Compositions and methods for the treatment of acute respiratory distress syndrome and inflammatory disorders | |
| CL2019001397A1 (en) | Improved stability of compositions containing urease inhibitor. | |
| EA201792346A1 (en) | APPLICATION of sGC STIMULATORS, sGC ACTIVATORS, SEPARATELY AND IN COMBINATION WITH PDE5 INHIBITORS, FOR THE TREATMENT OF PALCULAR ULCER (DU), ASSOCIATED TO SYSTEMIC SCLEROSE (SSc) | |
| AR104755A1 (en) | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASE | |
| CL2023001637A1 (en) | Jak1 pathway inhibitors for the treatment of vitiligo. |